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P U B L I S H E D B Y E L S E V I E R I N C .LETTERS TO THE EDITORIn Vivo Imaging of Hypoxia in
Atherosclerotic Plaques in HumansIn recognition of hypoxia’s involvement in athero-
genesis, it has been suggested that plaque hypoxia
be used as a target for molecular imaging to identify
high-risk patients, anticipate acute cardiovas-
cular events, and monitor atheroma therapies (1).
We demonstrate the potential of hypoxia imaging
in humans using a highly selective hypoxiaImaging in Atherosclerosis
his study were characterized by advanced atherosclerosis, as detected by the
8F-ﬂuorodeoxyglucose (FDG) uptake in the arterial wall, expressed as the ta
mography/computed tomography (PET/CT). As a marker of hypoxia, 18F-2-(4
hanced in both the carotid arteries as the aorta, quantiﬁed as HX4 TBR usin
orresponding MRI, CT, HX4-PET/CT, and FDG-PET/CT images in the most dis
uptake in patients (scale bars indicate 1 cm).marker, 18F-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-
1H-1,2,3-triazol-1-yl)propan-1-ol (HX4), for positron
emission tomography/computed tomography (PET/
CT) (2).
In 8 patients with carotid artery stenosis, we
performed multimodal imaging within 3 weeks, con-
sisting of: 1) magnetic resonance imaging (MRI) with a
3.0-T whole-body scanner (Intera, Philips, Best,
the Netherlands) to calculate the normalized wall
index (mean wall area/outer wall area) (3); 2)
18F-ﬂuorodeoxyglucose (FDG)-PET/CT (100 MBq);
and 3) HX4-PET/CT (100 MBq) imaging on a dedicated
scanner (Gemini, Philips) 90 min after tracer infusion.
FDG and HX4 uptake was quantiﬁed in the carotidelevated normalized wall index (NWI) on magnetic resonance imaging
rget-to-background ratio (TBR) in the index vessel measured with
-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol
g PET/CT (scale bars indicate 2 cm). A schematic of the analyzed
eased area of the plaque compared to nonplaque regions underscore
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1341arteries and aorta in regions with and without plaque,
providing a target-to-background ratio (TBR) as the
ratio of maximal/mean arterial wall standardized
uptake values andmean venous blood activity (3).
The included patients (4 men and 4 women; mean
age 68  6 years) had a history (>6 months) of tran-
sient ischemic attack (n ¼ 5), ischemic stroke (n ¼ 3),
and/or myocardial infarction (n ¼ 3). Patients had an
increased carotid wall thickness as shown by MRI,
providing a mean normalized wall index of 0.60 
0.07 (Figure 1). In addition, patients exhibited
enhanced FDG uptake at the level of both the carotid
arteries and aorta as assessed with PET/CT, as shown
by the increased maximal target-to-background
ratio for 18F-ﬂuorodeoxyglucose (FDGTBRmax) for the
carotid arteries (1.72  0.25) and aorta (2.61  0.64)
(Figure 1).
Subsequently, HX4 uptake was assessed at the level
of the carotid arteries in 4 patients and at the level of
the aorta in the other 4 patients (Figure 1). When
quantiﬁed, HX4TBRmax of the carotid arteries was
1.27  0.13 and 1.98  0.27 for the aorta (Figure 1). HX4
uptake was speciﬁc to plaque regions —HX4TBRmax
was 1.32  0.16 in the most diseased segment
compared with 1.15  0.20 in the nonplaque region
(p < 0.01) (Figure 1). Following the relationship
between plaque burden and hypoxia, we observed a
strong correlation between atherosclerotic HX4
uptake and carotid arterial wall dimensions (r ¼ 0.97;
p ¼ 0.04). In addition, we showed a correlation with
HX4 uptake and FDG uptake in the plaque (r ¼ 0.75;
p ¼ 0.03).
Taken together, we showed increased HX4 uptake
in plaque regions that correlated to arterial wall
dimensions and metabolic activity. Recently, a pre-
clinical PET study in atherosclerotic rabbits showed
positive correlations of the hypoxia tracer 18F-
ﬂuoromisonidazole to plaque burden and macrophage
content, but not to FDG uptake, which might
reﬂect distinct differences in rabbit and human
plaque composition (4). In support, previous work in
human carotid artery specimens showed in situ
correlations between a nonradioactive structural
analogue of HX4, pimonidazole, and features of
plaque vulnerability (5). Nonetheless, additional
studies are warranted to assess HX4’s relationship
with FDG and its direct link to hypoxia-associated
molecules in human plaques. Future studies are
aimed at: 1) using additional MRI imaging sequences
or MRI–traceable HX4 to overcome the low spatial
resolution of PET and provide greater insight in HX4
uptake in different plaque components; and 2)
addressing the relationship between HX4, hypoxia,
and plaque vulnerability in vivo.In conclusion, we present a noninvasive imaging
approach to visualize hypoxia in advanced athero-
sclerotic lesions in humans in vivo. Current data
support efforts to develop and implement imaging
modalities to quantify hypoxia in patients at risk for
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1258–65.Serial Multimodality Evaluation of
Aortocoronary Bypass Grafts During the
First Year After CABG SurgeryThe CABG-PRO (Cardiac Catheterization for Bypass
Graft Patency Rate Optimization) trial (NCT01063491),
was a randomized, controlled, double-blind, parallel-
group study of early versus no early graft angiography
in patients undergoing coronary artery bypass graft
(CABG) surgery. Enrollment in the CABG-PRO trial was
stopped early because of low rates of saphenous vein
graft (SVG) percutaneous coronary intervention
among patients undergoing early coronary angiog-
raphy (1 of 21 patients). Of those 21 patients, matched
